Abstract
Pancreatic cancer is highly aggressive with extremely poor prognosis. Developing a pancreatic cancer specific promoter (PCSP) is one approach for pancreatic cancer gene therapy. We have modified the promoter of cholecystokinin type A receptor (CCKAR), named CCK/Mpd, which possesses a relatively high activity in pancreatic cancer cells as compared with normal cells. The CCK/Mpd promoter-driven luciferase exhibits a better tumor specific tissue distribution than the CMV promoter-driven luciferase when systemically administered in vivo. Notably, we demonstrate a treatment efficacy by using CCK/Mpd-Bik-DD/liposome in a nude mice xenograft model, suggesting the feasibility of PCSP-based gene therapy in pancreatic cancer treatment.
Publication types
-
Comparative Study
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Apoptosis Regulatory Proteins / genetics*
-
Apoptosis Regulatory Proteins / metabolism
-
Cell Line, Tumor
-
Genetic Therapy / methods
-
Humans
-
Liposomes
-
Luciferases / genetics
-
Luciferases / metabolism
-
Mice
-
Mice, Nude
-
Mutation
-
Neoplasm Transplantation
-
Pancreatic Neoplasms / genetics
-
Pancreatic Neoplasms / metabolism
-
Pancreatic Neoplasms / pathology
-
Pancreatic Neoplasms / therapy*
-
Promoter Regions, Genetic*
-
Receptor, Cholecystokinin A / administration & dosage
-
Receptor, Cholecystokinin A / genetics*
-
Receptor, Cholecystokinin A / metabolism
-
Tissue Distribution
-
Transfection
Substances
-
Apoptosis Regulatory Proteins
-
Liposomes
-
Receptor, Cholecystokinin A
-
Luciferases